In 1950, mutant obese mice with a voracious
appetite were discovered by chance in a mouse colony at Jackson Laboratory in
Bar Harbor, Maine. These mice exhibited an (ob) genetic mutation. In the 1960s,
Douglas Coleman identified mice with both diabetic (db) and obese (ob) genetic
mutations. After extensive genetic inbreeding and testing, Coleman, in
collaboration with Rudolph Leibel, proposed that the obese (ob) mice lacked a
protein hormone regulating food intake and body weight, while the diabetic (db)
mice could produce the hormone but lacked the receptor to detect its signal.
In 1994, working at Rockefeller University,
Leibel and Jeffrey Friedman identified the gene and hormone responsible for
regulating food intake and body weight, naming the hormone leptin (from the
Greek word "leptos," meaning "thin"). The genetically
mutated obese mice lacked the ability to produce functional leptin, a protein
composed of 167 amino acids, primarily synthesized in fat cells. Leptin
functions in the hypothalamus to block neuropeptide Y (NPY), a feeding
stimulant, and promotes the synthesis of alpha-melanocyte-stimulating hormone
(MSH), which plays a role in appetite suppression and skin pigmentation.
Leptin is believed to be involved in the body's
adaptation to starvation. When body fat decreases, plasma leptin levels drop,
triggering an increase in feeding and a decrease in energy expenditure until
normal fat mass is restored. Initially, leptin was hoped to offer a solution
for weight reduction in obese individuals. However, human trials revealed that
despite frequent and high doses, leptin produced only modest weight loss. As a
protein, leptin must be injected since it is inactivated by stomach enzymes if
taken orally. The search for effective leptin-based treatments continues.
No comments:
Post a Comment